Noveris Health SciencesMYCOF 23 Market Cap is $41.24 Mil as of Jun. 30, 2026. GuruFocus rates MYCOF with a GF Score™ of 23/100. Among 1,020 Drug Manufacturers companies, Noveris Health Sciences ranks worse than 70.49% on this metric.
Noveris Health Sciences's quarterly market cap
declined
from Sep. 2025 ($0.40 Mil) to Dec. 2025 ($0.27 Mil) but then
increased
from Dec. 2025 ($0.27 Mil) to Mar. 2026 ($77.14 Mil).
Noveris Health Sciences's annual market cap
declined
from Dec. 2023 ($0.78 Mil) to Dec. 2024 ($0.17 Mil) but then
increased
from Dec. 2024 ($0.17 Mil) to Dec. 2025 ($0.27 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Noveris Health Sciences's Enterprise Value for Today is $40.11 Mil.
Noveris Health Sciences (OTCPK:MYCOF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Noveris Health Sciences Market Cap Related Terms
Noveris Health Sciences Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Noveris Health Sciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noveris Health Sciences (MYCOF) has a Market Cap of $41.24 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Noveris Health Sciences and its competitors. According to the industry distribution chart, Noveris Health Sciences ranks #719 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 70.5%.
Is Noveris Health Sciences' Market Cap too high?
Noveris Health Sciences' current Market Cap is $41.24 Mil. The Drug Manufacturers industry median Market Cap is 213.67. Noveris Health Sciences' value of $41.24 Mil is 80.7% below this industry median. Based on the distribution chart, Noveris Health Sciences ranks #719 out of 1020 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Noveris Health Sciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #719 out of 1020 companies for Market Cap. This places Noveris Health Sciences in the lower half of its industry. The industry median Market Cap is 213.67. Noveris Health Sciences' value of $41.24 Mil is 80.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.67, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noveris Health Sciences's current Market Cap of $41.24 Mil is 80.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current Market Cap is $41.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Noveris Health Sciences (MYCOF) has a current Market Cap of $41.24 Mil. The current Market Cap is $41.24 Mil and 80.7% below the Drug Manufacturers industry median of 213.67. Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Market Cap is $41.24 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score
Get the complete analysis for MYCOF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
